Obizur FDA Approval History
Obizur (antihemophilic factor [recombinant]) is an antihemophilic factor indicated for the treatment of bleeding episodes in adults with acquired hemophilia A.
Development Timeline for Obizur
|Oct 24, 2014||FDA Approves Obizur [Antihemophilic Factor (Recombinant)] for Acquired Hemophilia A|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.